Go Pro
→ He bet half his $9 billion on ONE stock (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dynatronics Co. stock logo
DYNT
Dynatronics
$0.01
$0.04
▼
$0.19
$653K0.311,976 shsN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$3.96
+12.5%		$4.39
$2.90
▼
$23.42
$26.64M1.4116,506 shs138,698 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dynatronics Co. stock logo
DYNT
Dynatronics
0.00%0.00%0.00%0.00%-87.66%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
+12.50%+9.09%-2.22%-33.45%-75.93%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dynatronics Co. stock logo
DYNT
Dynatronics
$0.01
$0.04
▼
$0.19
$653K0.311,976 shsN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$3.96
+12.5%		$4.39
$2.90
▼
$23.42
$26.64M1.4116,506 shs138,698 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dynatronics Co. stock logo
DYNT
Dynatronics
0.00%0.00%0.00%0.00%-87.66%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
+12.50%+9.09%-2.22%-33.45%-75.93%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dynatronics Co. stock logo
DYNT
Dynatronics
0.00
N/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
2.43
Hold$56.401,324.24% Upside

Current Analyst Ratings Breakdown

Latest DYNT and PSTV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/8/2026
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
Ascendiant Capital Markets logo
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$65.00 ➝ $57.00
(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dynatronics Co. stock logo
DYNT
Dynatronics
$33.60M0.00N/AN/A$0.57 per share0.00
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/AN/AN/AN/A$0.72 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dynatronics Co. stock logo
DYNT
Dynatronics
-$2.70M-$1.35N/AN/AN/A-8.35%-41.81%-9.56%N/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$22.39M-$2.30N/AN/AN/A-230.24%-198.48%-73.13%8/13/2026 (Estimated)

Latest DYNT and PSTV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$0.88N/AN/AN/A$1.11 millionN/A
5/15/2026Q1 2026
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$0.8480-$1.05-$0.2020-$1.05$0.97 million$1.03 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Dynatronics Co. stock logo
DYNT
Dynatronics
N/AN/AN/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dynatronics Co. stock logo
DYNT
Dynatronics
0.25
1.21
0.60
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/A
2.27
2.27

Institutional Ownership

CompanyInstitutional Ownership
Dynatronics Co. stock logo
DYNT
Dynatronics
4.18%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
3.28%

Insider Ownership

CompanyInsider Ownership
Dynatronics Co. stock logo
DYNT
Dynatronics
2.90%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
2.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dynatronics Co. stock logo
DYNT
Dynatronics
20016.05 million8.11 millionNot Optionable
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
206.88 million6.71 millionNot Optionable

Recent News About These Companies

Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Average Recommendation of "Hold" from Brokerages
August 3 at 4:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30938887
Plus Therapeutics Inc.: Cerenome Launches as an Integrated CNS Oncology Company
July 31, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69184715-plus-therapeutics-inc-cerenome-launches-as-an-integrated-cns-oncology-company-399.htm
Cerenome Launches as an Integrated CNS Oncology Company
July 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/31/3336793/0/en/cerenome-launches-as-an-integrated-cns-oncology-company.html
Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference
July 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/28/3334137/0/en/plus-therapeutics-announces-scientific-presentations-and-sponsored-symposium-at-2026-sno-asco-cns-metastases-conference.html
Plus Therapeutics Inc.: Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide Cerebrospinal Fluid Assay for Metastatic CNS Cancer
July 21, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69082107-plus-therapeutics-inc-plus-therapeutics-secures-regional-coverage-agreement-with-medical-mutual-for-cnside-cerebrospinal-fluid-assay-for-metastatic-399.htm
Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330332/0/en/plus-therapeutics-secures-regional-coverage-agreement-with-medical-mutual-for-cnside-cerebrospinal-fluid-assay-for-metastatic-cns-cancer.html
Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
July 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/16/3328365/0/en/plus-therapeutics-and-genomic-testing-cooperative-partner-to-integrate-next-generation-sequencing-into-the-cnside-csf-assay-platform.html
Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring
July 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/14/3326729/0/en/plus-therapeutics-highlights-nccn-cns-cancers-guidelines-update-and-reinforces-clinical-role-of-cnside-in-leptomeningeal-metastases-monitoring.html
Plus Therapeutics Inc.
July 2, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/pstv/company-people?gaa_at=eafs&gaa_n=AWEtsqcSV2x2NL1k-FvQMUTLjCm9qt-_bJJ_1_2r9FxRrNgAlW_bC1uzmtgq&gaa_sig=T1Ip-AMMiw2TMzDxXKCsR9rYhO1gZzPl_nOgdSHfFcUk0jp52cFxY590K7kKhbdwn22qO3__695j0roHw1buuw%25253D%25253D&gaa_ts=69b47cee
Plus Therapeutics to rebrand as Cerenome and adopt CNSY ticker on August 3 (PSTV)
June 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/plus-therapeutics-rebrand-cerenome-adopt-124948664.html
Plus Therapeutics, Inc. (PSTV) Discusses Rebranding and Integrated CNS Oncology Platform Strategy Transcript
June 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4918866-plus-therapeutics-inc-pstv-discusses-rebranding-and-integrated-cns-oncology-platform-strategy
Plus Therapeutics to Rebrand as Cerenome, Affirm 2026 Guidance and Report CNSide Commercial Progress
June 30, 2026  |  quiverquant.comQ
Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding
June 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/30/3319554/0/en/plus-therapeutics-provides-mid-year-business-update-including-corporate-rebranding.html
Plus Therapeutics Subsidiary CNSide Diagnostics Signs National Coverage Agreement with Elevance Health for CNSide CSF Tumor Cell Enumeration Assay
June 25, 2026  |  quiverquant.comQ
Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
June 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/25/3317434/0/en/plus-therapeutics-secures-national-coverage-agreement-with-elevance-health-for-cnside-cerebrospinal-fluid-assay-for-metastatic-cns-cancer.html
Plus Therapeutics to Provide Business Update Call on June 30, 2026
June 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/23/3315850/0/en/plus-therapeutics-to-provide-business-update-call-on-june-30-2026.html
Plus Therapeutics Launches New At-The-Market Equity Program
June 5, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/plus-therapeutics-launches-new-at-the-market-equity-program?utm_source=marketbeat.com&utm_medium=referral
Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform
June 4, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1093474?snapi
CNSide Diagnostics, a Plus Therapeutics Subsidiary, Achieves Prestigious CAP Accreditation for Clinical Laboratory
June 4, 2026  |  quiverquant.comQ
Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory
June 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/04/3306660/0/en/plus-therapeutics-announces-cap-accreditation-of-cnside-diagnostics-clinical-laboratory.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Dynatronics stock logo

Dynatronics NASDAQ:DYNT

Dynatronics Corporation, a medical device company, designs, manufactures, and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the United States. The company offers orthopedic soft bracing products include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products. It also offers physical therapy and rehabilitation products, which include therapeutic modality devices comprising electrotherapy, ultrasound, phototherapy, traction, hot and cold therapy, and electrodes; and power and manually operated treatment tables, mat platforms, work tables, parallel bars, training stairs, weight racks, and other related equipment. In addition, the company manufactures and distributes clinical supplies, including exercise bands and tubing, lotions and gels, orthopedic bracings, paper products, and other related supplies. It markets its products under the Dynatron, Dynatron Solaris, Dynaheat, BodyIce, Powermatic, Bird & Cronin, Physician's Choice, Hausmann, PROTEAM, and Mammoth brands. The company sells its products to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and retail distributors and equipment manufacturers. It also exports its products in Asia, Latin America, and the Middle East. Dynatronics Corporation was founded in 1979 and is headquartered in Eagan, Minnesota.

Plus Therapeutics stock logo

Plus Therapeutics NASDAQ:PSTV

$3.96 +0.44 (+12.50%)
As of 08/4/2026

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas